<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037061</url>
  </required_header>
  <id_info>
    <org_study_id>13-1413</org_study_id>
    <nct_id>NCT02037061</nct_id>
  </id_info>
  <brief_title>Reducing Post-Op Pain After Sacrospinous Ligament Colpopexy</brief_title>
  <official_title>A Randomized Control Trial on the Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Colpopexy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to determine if intraoperative local analgesia&#xD;
      administered at the level of the sacrospinous ligament can lessen the gluteal pain felt by&#xD;
      patients postoperatively after SSL colpopexy.&#xD;
&#xD;
      Hypothesis: Local analgesia administered at the level of the sacrospinous ligament can lessen&#xD;
      the gluteal pain felt by patients postoperatively after SSL colpopexy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blind clinical trial. Potential subjects will be identified by&#xD;
      members of the Center for Urogynecology and Pelvic Reconstructive Surgery at the Cleveland&#xD;
      Clinic main campus. Eligible patients that agree to participate will be provided written&#xD;
      informed consent administered by the collaborators listed on the IRB at the Cleveland Clinic&#xD;
      main campus.&#xD;
&#xD;
      All subjects will be predetermined by their surgeon to undergo sacrospinous ligament&#xD;
      colpopexy for management of vaginal apex prolapse after hysterectomy. The participants will&#xD;
      then be randomized to one of two groups: &quot;local analgesia injection&quot; or &quot;normal saline&#xD;
      injection&quot; according to a computer-generated randomization schedule with random block sizes&#xD;
      with the use of the SAS statistical software package (SAS Institute, Cary, NC). Randomization&#xD;
      will be done by a nurse coordinator who will not be involved in participant recruitment or&#xD;
      injection at the time of surgery. All patients and providers will be blinded to their&#xD;
      assignment. The assignment will be kept in an envelope which will be given to the pharmacy&#xD;
      the day of the patient's scheduled procedure. The pharmacy will then dispense the correct&#xD;
      intervention based on the randomization.&#xD;
&#xD;
      In addition to a standardized evaluation including the history and physical examination,&#xD;
      patients will be asked to complete a functional assessment questionnaire as well as a&#xD;
      surgical pain scale at the preoperative visit. Prior to discharge from the hospital, patients&#xD;
      will be provided with an envelope with pre-labeled questionnaires to bring home with them.&#xD;
      Prior to discharge, they will be asked to complete the surgical pain scale only. Subjects&#xD;
      will then be called the day after discharge, at week 1, week 2, week 4 and week 6 after the&#xD;
      procedure and will be reminded to complete the appropriate questionnaires/forms that were&#xD;
      provided to them. They will bring in these forms to their 6-week postoperative visit. All&#xD;
      questionnaires will be self-administered. Completion of these questionnaires is the only&#xD;
      additional assessment that is specific to participation in this study and is not usually&#xD;
      included as part of the standard care of sacrospinous ligament colpopexy.&#xD;
&#xD;
      Sacrospinous ligament colpopexy will be performed in a standard fashion. The approach is done&#xD;
      by either entering the vagina along the anterior or posterior wall or at the apex. Approach&#xD;
      and side of the suspension will be based on surgeon's preference. Prior to entry, the apex of&#xD;
      the vaginal vault is first identified by visualizing the old hysterectomy scar. Allis clamps&#xD;
      are used to demarcate the new vaginal apex and to ensure that this apex will suspend&#xD;
      adequately to the sacrospinous ligament, which is identified transvaginally by palpation of&#xD;
      the ischial spine. Once vaginal entry is made, sharp and blunt dissection are performed down&#xD;
      to the pararectal space on one or both sides. Identification of the ischial spine confirms&#xD;
      the position of the coccygeus-sacrospinous ligament complex. Once the complex is freed of any&#xD;
      overlying areolar tissue, a Briesky Navratil retractor is placed to retract the rectum away&#xD;
      from the site of suture placement and to help with visualization of the ligament complex.&#xD;
&#xD;
      The CapioTM device is then used to place the suspension sutures. 3 sutures are placed: 2&#xD;
      delayed-absorbable (0 PDS) and 1 permanent (0 prolene). All sutures are placed one and a half&#xD;
      to two fingerbreadths (2-3cm) medial to the ischial spine in a sequential fashion. After&#xD;
      placement, a rectal exam is done to ensure that no sutures have been placed through the&#xD;
      rectum and the coccygeus-sacrospinous ligament complex is visualized carefully to ensure that&#xD;
      the surgical site is hemostatic. The absorbable-delayed suspension sutures are placed through&#xD;
      the vaginal epithelium at the level of the neoapex and all permanent sutures are placed&#xD;
      through the subepithelial tissue.&#xD;
&#xD;
      Injection of the sacrospinous ligament will be performed prior to tying down the suspension&#xD;
      sutures according to the group the patient is randomized to. A pudendal nerve block kit&#xD;
      needle and syringe will be used to administer the injection. The spacer will be removed,&#xD;
      allowing the needle point to enter the ligament 10mm in depth with each injection. The&#xD;
      injection will be placed in 3 locations (~3mL in each injection for a total of 10mL) along&#xD;
      the center of the sacropinous ligament under each previously placed suture. Proper injection&#xD;
      technique will be performed with each injection (e.g. there will be confirmation of&#xD;
      extravascular placement of the needle tip prior to each injection). One of two injections&#xD;
      (bupivacaine vs. normal saline) delivered by the pharmacy will be administered depending upon&#xD;
      the group to which the patient has been randomized.&#xD;
&#xD;
      Preoperative data will include the following:&#xD;
&#xD;
        -  Patient age, race, vaginal parity, menopausal sate, tobacco use, BMI, prior prolapse&#xD;
           surgery, preoperative prolapse stage (see Appendix for demographic data sheet)&#xD;
&#xD;
        -  Assessment of functional status, surgical pain scale&#xD;
&#xD;
        -  Labs (Hb/Hct)&#xD;
&#xD;
      Intraoperative data will include the following:&#xD;
&#xD;
        -  Surgery date&#xD;
&#xD;
        -  Surgeon&#xD;
&#xD;
        -  Side of Colpopexy&#xD;
&#xD;
        -  Concomitant procedures&#xD;
&#xD;
        -  EBL&#xD;
&#xD;
      Postoperative data will include the following:&#xD;
&#xD;
        -  Days in the hospital&#xD;
&#xD;
        -  Pain medication requirment during hospitalization&#xD;
&#xD;
        -  Prior to discharge from hospital: surgical pain scale; localization of pain&#xD;
&#xD;
        -  POD#1: Labs (Hb/Hct)&#xD;
&#xD;
        -  Time from surgery [incision] to discharge (hours)&#xD;
&#xD;
        -  1st postoperative week oDaily surgical pain scale with localization of pain oDaily pain&#xD;
           medication use oAt end of week 1: Assessment of functional status&#xD;
&#xD;
        -  2nd postoperative week oDaily surgical pain scale with localization of pain oDaily pain&#xD;
           medication use oAt end of week 2: Assessment of functional status&#xD;
&#xD;
        -  4th postoperative week (at end of week 4) oAssessment of functional status oSurgical&#xD;
           pain scale with localization of pain&#xD;
&#xD;
        -  6th postoperative week (at end of week 6) oAssessment of functional status oSurgical&#xD;
           pain scale with localization of pain&#xD;
&#xD;
        -  Date of 6-week postoperative&#xD;
&#xD;
        -  Need for intervention for pain: trigger point injection, PFPT referral, reoperation&#xD;
&#xD;
      All paper forms used for data collection will be kept in a research cabinet dedicated to this&#xD;
      project which will be locked at all times, in a locked office at the Cleveland Clinic. All&#xD;
      forms will contain de-identified information - identification numbers will correspond to the&#xD;
      subjects listed in the master excel file.&#xD;
&#xD;
      All study data will be transferred and managed electronically using REDCap (Research&#xD;
      Electronic Data Capture). Each subject will be entered into REDCap using the assigned&#xD;
      identification number from the master excel file. REDCap is a secure, web-based application&#xD;
      designed to support data capture for research studies, providing user-friendly web-based case&#xD;
      report forms, real-time data entry validation, audit trials, and a de-identified data export&#xD;
      mechanism to common statistical packages. They system was developed by a multi-institutional&#xD;
      consortium which was initiated at Vanderbilt University and includes the Cleveland Clinic.&#xD;
      The database is hosted at the Cleveland Clinic Research Datacenter in the JJN basement and is&#xD;
      managed by the Quantitative Health Sciences Department. The system is protected by a login&#xD;
      and Secure Sockets Layers (SSL) encryption. Data collection is customized for each study as&#xD;
      based on a study-specific data dictionary defined by the research team with guidance from the&#xD;
      REDCap administrator in Quantitative Health Sciences at the Cleveland Clinic&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Gluteal Pain</measure>
    <time_frame>6-weeks</time_frame>
    <description>Pain measured using a pain numeric rating scale from 0 to 10 (0=no pain, 10= worst pain imaginable)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Intervention for Postoperative Pain</measure>
    <time_frame>6-weeks</time_frame>
    <description>Need for intervention through the use of trigger point injection, referral to pelvic floor physical therapy, or reoperation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Pain Beyond Day of Discharge</measure>
    <time_frame>6 weeks</time_frame>
    <description>Pain measured using the pain numeric rating scale from 0-10 (0=no pain, 10= worst pain imaginable)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.</description>
    <arm_group_label>bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <arm_group_label>normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18, who are to undergo sacrospinous ligament colpopexy for vaginal apex prolapse&#xD;
             after hysterectomy&#xD;
&#xD;
          -  Other concomitant prolapse and anti-incontinence procedures (e.g., anterior&#xD;
             colporrhaphy, paravaginal defect repair, posterior colporrhaphy, or mid-urethral sling&#xD;
             procedures) will be performed at the primary surgeon's discretion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comprehend written and/or spoken English&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Need for concomitant surgeries not related to pelvic organ prolapse or incontinence&#xD;
&#xD;
          -  Chronic pain conditions (e.g., fibromyalgia, myositis, myofascial pain syndrome)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecile Unger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <results_first_submitted>May 5, 2017</results_first_submitted>
  <results_first_submitted_qc>July 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2019</results_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Saline</title>
          <description>Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.&#xD;
Normal Saline</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine</title>
          <description>Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.&#xD;
Bupivacaine: Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Saline</title>
          <description>Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.&#xD;
Normal Saline</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine</title>
          <description>Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.&#xD;
Bupivacaine: Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="7"/>
                    <measurement group_id="B2" value="63" spread="9"/>
                    <measurement group_id="B3" value="66" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Postoperative Gluteal Pain</title>
        <description>Pain measured using a pain numeric rating scale from 0 to 10 (0=no pain, 10= worst pain imaginable)</description>
        <time_frame>6-weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
            <description>Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.&#xD;
Normal Saline</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine</title>
            <description>Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.&#xD;
Bupivacaine: Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Gluteal Pain</title>
          <description>Pain measured using a pain numeric rating scale from 0 to 10 (0=no pain, 10= worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean gluteal pain in immediate post op</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="2.7"/>
                    <measurement group_id="O2" value="4.0" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean gluteal pain within week 1 of procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.4"/>
                    <measurement group_id="O2" value="2.0" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean gluteal pain 2 weeks after procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.3"/>
                    <measurement group_id="O2" value="1.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean gluteal pain 4 weeks after procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.5"/>
                    <measurement group_id="O2" value="0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean gluteal pain 6 weeks after procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Intervention for Postoperative Pain</title>
        <description>Need for intervention through the use of trigger point injection, referral to pelvic floor physical therapy, or reoperation</description>
        <time_frame>6-weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
          </group>
          <group group_id="O2">
            <title>Bupivicaine</title>
          </group>
        </group_list>
        <measure>
          <title>Need for Intervention for Postoperative Pain</title>
          <description>Need for intervention through the use of trigger point injection, referral to pelvic floor physical therapy, or reoperation</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trigger point injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Referral to pelvic floor physical therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reoperation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Pain Beyond Day of Discharge</title>
        <description>Pain measured using the pain numeric rating scale from 0-10 (0=no pain, 10= worst pain imaginable)</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Saline</title>
          </group>
          <group group_id="O2">
            <title>Bupivicaine</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Pain Beyond Day of Discharge</title>
          <description>Pain measured using the pain numeric rating scale from 0-10 (0=no pain, 10= worst pain imaginable)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean overall pain 2 weeks after procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.3"/>
                    <measurement group_id="O2" value="1.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean overall pain 4 weeks after procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean overall pain 6 weeks after procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.1"/>
                    <measurement group_id="O2" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Normal Saline</title>
          <description>Intraoperatively the patient will receive 10ml of normal saline injected into the sacrospinous ligament.&#xD;
Normal Saline</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine</title>
          <description>Intraoperatively the patient will receive 10 ml of bupivacaine injected into the sacrospinous ligament.&#xD;
Bupivacaine: Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cecile Unger</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-444-0542</phone>
      <email>ungerc@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

